Table 1 |
|
|
Patient and tumor characteristics |
|
| Characteristic |
Number of patients (percentage) |
|
|
|
| Age |
|
| <50 years |
19 (42) |
| ≥50 years |
26 (58) |
| HER-2a |
|
| IHC (score 3+) |
26 (58) |
| FISH-positive |
42 (95) |
| Estrogen receptor-positive |
|
| Yes |
17 (38) |
| No |
28 (62) |
| Progesterone receptor-positive |
|
| Yes |
10 (22) |
| No |
35 (78) |
| Nuclear grade |
|
| Intermediate |
14 (31) |
| High |
31 (69) |
| Tumor size (baseline) |
|
| T1 |
5 (11) |
| T2 |
24 (53) |
| T3 |
8 (18) |
| T4 |
8 (18) |
| Nodal status (baseline) |
|
| N0 |
19 (42) |
| N1-N3 |
26 (58) |
|
|
|
|
aAll tumors were HER-2-positive by either IHC (score, 3+) and/or FISH. Not every patient had both tests. Two tumors were 2+ by IHC and positive by FISH, and one tumor was 3+ by IHC and negative by FISH. FISH, fluorescence in situ hybridization; IHC, immunohistochemistry. |
|
|
Esteva et al. Breast Cancer Research 2007 9:R87 doi:10.1186/bcr1836 |
|
